Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis.
Anoikis
CRISPR/Cas9
Extracellular matrix
Integrin-FAK-Src
Metastasis
PCMT1
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
15 Jan 2022
15 Jan 2022
Historique:
received:
29
08
2021
accepted:
30
12
2021
entrez:
16
1
2022
pubmed:
17
1
2022
medline:
22
3
2022
Statut:
epublish
Résumé
The development of lethal cancer metastasis depends on the dynamic interactions between cancer cells and the tumor microenvironment, both of which are embedded in the extracellular matrix (ECM). The acquisition of resistance to detachment-induced apoptosis, also known as anoikis, is a critical step in the metastatic cascade. Thus, a more in-depth and systematic analysis is needed to identify the key drivers of anoikis resistance. Genome-wide CRISPR/Cas9 knockout screen was used to identify critical drivers of anoikis resistance using SKOV3 cell line and found protein-L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1) as a candidate. Quantitative real-time PCR (qRT-PCR) and immune-histochemistry (IHC) were used to measure differentially expressed PCMT1 in primary tissues and metastatic cancer tissues. PCMT1 knockdown/knockout and overexpression were performed to investigate the functional role of PCMT1 in vitro and in vivo. The expression and regulation of PCMT1 and integrin-FAK-Src pathway were evaluated using immunoprecipitation followed by mass spectrometry (IP-MS), western blot analysis and live cell imaging. We found that PCMT1 enhanced cell migration, adhesion, and spheroid formation in vitro. Interestingly, PCMT1 was released from ovarian cancer cells, and interacted with the ECM protein LAMB3, which binds to integrin and activates FAK-Src signaling to promote cancer progression. Strikingly, treatment with an antibody against extracellular PCMT1 effectively reduced ovarian cancer cell invasion and adhesion. Our in vivo results indicated that overexpression of PCMT1 led to increased ascites formation and distant metastasis, whereas knockout of PCMT1 had the opposite effect. Importantly, PCMT1 was highly expressed in late-stage metastatic tumors compared to early-stage primary tumors. Through systematically identifying the drivers of anoikis resistance, we uncovered the contribution of PCMT1 to focal adhesion (FA) dynamics as well as cancer metastasis. Our study suggested that PCMT1 has the potential to be a therapeutic target in metastatic ovarian cancer.
Sections du résumé
BACKGROUND
BACKGROUND
The development of lethal cancer metastasis depends on the dynamic interactions between cancer cells and the tumor microenvironment, both of which are embedded in the extracellular matrix (ECM). The acquisition of resistance to detachment-induced apoptosis, also known as anoikis, is a critical step in the metastatic cascade. Thus, a more in-depth and systematic analysis is needed to identify the key drivers of anoikis resistance.
METHODS
METHODS
Genome-wide CRISPR/Cas9 knockout screen was used to identify critical drivers of anoikis resistance using SKOV3 cell line and found protein-L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1) as a candidate. Quantitative real-time PCR (qRT-PCR) and immune-histochemistry (IHC) were used to measure differentially expressed PCMT1 in primary tissues and metastatic cancer tissues. PCMT1 knockdown/knockout and overexpression were performed to investigate the functional role of PCMT1 in vitro and in vivo. The expression and regulation of PCMT1 and integrin-FAK-Src pathway were evaluated using immunoprecipitation followed by mass spectrometry (IP-MS), western blot analysis and live cell imaging.
RESULTS
RESULTS
We found that PCMT1 enhanced cell migration, adhesion, and spheroid formation in vitro. Interestingly, PCMT1 was released from ovarian cancer cells, and interacted with the ECM protein LAMB3, which binds to integrin and activates FAK-Src signaling to promote cancer progression. Strikingly, treatment with an antibody against extracellular PCMT1 effectively reduced ovarian cancer cell invasion and adhesion. Our in vivo results indicated that overexpression of PCMT1 led to increased ascites formation and distant metastasis, whereas knockout of PCMT1 had the opposite effect. Importantly, PCMT1 was highly expressed in late-stage metastatic tumors compared to early-stage primary tumors.
CONCLUSIONS
CONCLUSIONS
Through systematically identifying the drivers of anoikis resistance, we uncovered the contribution of PCMT1 to focal adhesion (FA) dynamics as well as cancer metastasis. Our study suggested that PCMT1 has the potential to be a therapeutic target in metastatic ovarian cancer.
Identifiants
pubmed: 35033172
doi: 10.1186/s13046-022-02242-3
pii: 10.1186/s13046-022-02242-3
pmc: PMC8760697
doi:
Substances chimiques
PCMT1 protein, human
EC 2.1.1.77
Protein D-Aspartate-L-Isoaspartate Methyltransferase
EC 2.1.1.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Subventions
Organisme : Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support
ID : 20172003
Organisme : Natural Science Foundation of Shanghai
ID : 20ZR1433700
Organisme : National Natural Science Foundation of China
ID : 81872345
Organisme : Innovative Research Team of High-Level Local Universities in Shanghai
ID : SSMU-ZDCX20180800
Informations de copyright
© 2022. The Author(s).
Références
Gene. 1999 Nov 29;240(2):333-41
pubmed: 10580153
Int J Mol Sci. 2018 Oct 04;19(10):
pubmed: 30287763
Nat Commun. 2017 Mar 06;8:14470
pubmed: 28262727
IUBMB Life. 2018 Apr;70(4):291-299
pubmed: 29517839
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
J Biol Chem. 1999 Jul 16;274(29):20671-8
pubmed: 10400700
Onco Targets Ther. 2017 Dec 21;11:37-46
pubmed: 29317832
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20380-5
pubmed: 19091943
Exp Cell Res. 1998 May 1;240(2):282-92
pubmed: 9597001
Protein Sci. 2005 Feb;14(2):452-63
pubmed: 15659375
Sci Rep. 2018 Feb 9;8(1):2718
pubmed: 29426928
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):207-228
pubmed: 30316942
Ageing Res Rev. 2003 Jul;2(3):263-85
pubmed: 12726775
Cell Mol Life Sci. 2003 Jul;60(7):1281-95
pubmed: 12943218
Neuroscience. 2015 Jun 4;295:139-50
pubmed: 25800307
Nat Rev Cancer. 2016 Apr;16(4):201-18
pubmed: 27009393
Oncotarget. 2016 Aug 11;9(2):1656-1672
pubmed: 29416721
Tumour Biol. 2014 Nov;35(11):11301-9
pubmed: 25119594
Mol Aspects Med. 2010 Apr;31(2):205-14
pubmed: 20153362
Mol Ther. 2018 Nov 7;26(11):2592-2603
pubmed: 30122422
PLoS One. 2015 Aug 04;10(8):e0134789
pubmed: 26241740
Cell. 2009 Jul 23;138(2):389-403
pubmed: 19615732
Transl Stroke Res. 2017 May 22;:
pubmed: 28534197
Proteomics. 2013 May;13(10-11):1667-1671
pubmed: 23533145
Nat Biomed Eng. 2018 Nov;2(11):850-864
pubmed: 31015614
Cancer Res. 2006 Nov 1;66(21):10233-7
pubmed: 17079438
Curr Aging Sci. 2011 Feb;4(1):8-18
pubmed: 21204776
Nat Protoc. 2017 Apr;12(4):828-863
pubmed: 28333914
Anticancer Res. 2017 Jan;37(1):47-55
pubmed: 28011472
Hum Pathol. 2016 Apr;50:1-10
pubmed: 26997432
J Proteomics. 2014 Jun 25;106:191-204
pubmed: 24769233
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 28096261
Nat Commun. 2012 Jun 26;3:927
pubmed: 22735455
Nature. 2011 Dec 07;481(7379):85-9
pubmed: 22158103
EMBO J. 2012 Jan 18;31(2):254-6
pubmed: 22179697
Ann Dermatol. 2017 Apr;29(2):243-246
pubmed: 28392661
Cell Biol Toxicol. 2018 Aug;34(4):321-332
pubmed: 29127567
Clin Sci (Lond). 2011 Aug;121(4):159-68
pubmed: 21413933
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
J BUON. 2015 May;20 Suppl 1:S2-11
pubmed: 26051329
Cell Death Dis. 2016 Dec 29;7(12):e2572
pubmed: 28032865
J Biol Chem. 2010 Jan 15;285(3):2028-39
pubmed: 19887451